喂养型代谢综合征小鼠及大鼠模型的建立方法探讨

目的探讨与人类代谢综合征(metabolic syndrome,MS)临床特征相似的啮齿类动物模型的建立方法,考察造模条件,建立经济、简便、稳定可靠的代谢综合征药物筛选模型。方法高热量饲料喂养KM、C57BL/6、BALB/c小鼠6～8wk,喂养Wistar大鼠23wk,动态监测空腹血清总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)、血糖(fasting blood glucose,FBG)、胰岛素(fasting insulin,FINS)含量,计算稳态模型胰岛素抵抗评价指数(homeostasis model assessment of insulin resistance,HOMA-IR)。实验结束时做口服葡萄糖耐量试验(oral glucose tolerance test,OGTT),称取动物内脏脂肪重量(visceral fat mass,VFM)并计算内脏脂肪系数(visceral fat coefficient,VFC)。结果高热量饲料喂养KM、C57BL/6、BALB/c小鼠及Wistar大鼠均表现出TC、LDL-C、FBG增高和葡萄糖耐量减低的糖脂代谢紊乱。高热量饲料使KM鼠形成腹型肥胖和胰岛素抵抗。C57BL/6小鼠未能形成肥胖,BALB/c小鼠形成整体型肥胖。Wistar大鼠形成腹型肥胖,喂养2～6wk形成脂代谢紊乱、10wk后表现出糖代谢紊乱及胰岛素抵抗,且大鼠摄食重量下降,下丘脑神经肽Y含量增加。结论喂养型KM小鼠具有腹型肥胖、糖脂代谢紊乱和胰岛素抵抗的特征,与人类临床特征相似,符合MS定义要求,适于作为MS治疗和干预药物的快速筛选模型。     

高脂高糖诱导脂肪肝胰岛素抵抗大鼠模型的建立

目的高脂乳剂灌胃并配合自由饮用糖水建立脂肪肝胰岛素抵抗大鼠模型。方法SD大鼠灌胃高脂乳剂及自由饮用浓度为180g.L-1的蔗糖水,每日1次,连续10wk。观察大鼠体重等一般状况;检测肝脏TG和FFA的含量;血清ALT、AST、FFA、HDL-C、LDL-C、葡萄糖(FBG)和胰岛素(FINS)水平以及肝脏的病理形态学变化。结果模型组大鼠肝脏TG、FFA含量升高,血清LDL-C、FFA、FBG、FINS含量升高,血清HDL-C降低,IRI水平升高,ISI水平降低,出现胰岛素抵抗。造模6wk末肝脏病理形态学显示出单纯性脂肪肝,8wk末为轻中度脂肪性肝炎,10wk末为中重度脂肪性肝炎。结论灌胃高脂乳剂及饮用高糖饮料10wk,可成功建立脂肪肝胰岛素抵抗大鼠模型。     

黄连素通过对高脂小鼠肝脏、胰腺中PCSK9和LDLR的不同调控改善高脂血症和高胰岛素血症

目的 观察黄连素对高脂小鼠肝脏、胰腺中PCSK9和LDLR的不同调控，探讨其减缓高脂血症和高胰岛素血症的新作用机制。方法 SPF级C57BL/6J小鼠随机分为3组：正常对照组(普通饮食喂养)、高脂饲料组(高脂饮食喂养)、黄连素组(高脂饮食喂养同时灌胃黄连素)。自动血糖仪检测空腹血糖值；酶联免疫法(ELISA)测空腹血清胰岛素水平，计算血糖与胰岛素比值。ELISA测空腹血清PCSK9水平；酶标仪和相应的试剂盒检测血清中的甘油三酯、总胆固醇、高密度胆固醇、低密度胆固醇的含量。HE染色法观察肝脏和胰腺的组织形态变化。Western blotting检测肝脏和胰腺中PCSK9和LDLR蛋白的表达。结果 黄连素能降低血清中胆固醇的含量，同时明显降低血浆中PCSK9的含量，减少肝脏PCSK9蛋白表达，增加肝脏表面LDLR蛋白表达；改善高脂诱导的胰岛素抵抗，减少胰岛细胞肥大及空泡数量，增加胰腺表面PCSK9蛋白表达，减少胰腺表面LDLR蛋白表达。结论 黄连素调节高脂饮食小鼠PCSK9的表达和分泌，具有组织特异性，在肝脏中增强LDLR介导的胆固醇细胞摄取，同时在胰腺中抑制LDLR介导的胆固醇摄取，从而改善高脂饮食诱导的肝脏脂肪性病变和胰岛素抵抗。     

茵陈蒿提取物对高脂诱导大鼠增强胰岛素敏感性及抗脂肪肝作用的研究

目的:研究茵陈蒿提取物对高脂诱导大鼠增强胰岛素敏感性及抗脂肪肝的作用。方法:采用高脂、高糖饲料喂养大鼠,饲养8wk后测定大鼠空腹血糖(FBG)和2h后血糖(2hBG)值,并按血糖值将大鼠随机分为模型组、二甲双胍组(0.2 g·kg~(-1))及茵陈蒿提取物高(6.9g·kg~(-1))、低(2.3g·kg~(-1))剂量组。连续灌胃给药4wk后,测定大鼠FBG和血清胰岛素水平;测定血浆三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、游离脂肪酸(FFA)水平;测定天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)活性和抗氧化能力等;评估肝组织脂肪变性情况。结果:茵陈蒿提取物高剂量组大鼠FBG和血清胰岛素水平显著低于模型组,胰岛素敏感指数(ISI)和胰岛素抵抗指数(IRI)恢复正常(P<0.05);能显著提高超氧化物歧化酶(SOD)活性和降低丙二醛(MDA)含量,降低TC、TG、FFA和LDL-C水平,升高HDL-C水平;同时显著降低AST和ALT活性,改善肝脏脂肪病变。结论:茵陈蒿提取物对胰岛素抵抗(IR)-脂肪肝具有降低血脂和保肝作用,其作用机制可能与其提高抗氧化能力、恢复胰岛素敏感性有关。     

糖尿病性肥胖大鼠模型的建立及西布曲明对其治疗作用的研究

目的:研究链脲佐菌素(STZ)联合高营养饲料诱导的大鼠糖尿病性肥胖模型的特点,以及盐酸西布曲明对此种模型的治疗作用。方法:先用小剂量STZ(25mg/kg)尾静脉注射诱导大鼠产生糖尿病,再用高营养饲料喂养4个月建立糖尿病性肥胖模型。盐酸西布曲明4mg/kg灌胃治疗17d,给药期间定时测定体重及摄食量,15d时测定糖耐量,实验终点时测定体重、内脏脂肪及右比目鱼肌重量;取血分离血清测定血脂、血糖和血清胰岛素水平,并计算胰岛素抵抗指数。结果:模型组大鼠体重、内脏脂肪重量及系数均显著升高,而右比目鱼肌系数显著降低;空腹血糖、血胰岛素水平显著升高,并出现糖耐量异常及胰岛素抵抗;TG水平显著升高,而高密度脂蛋白胆固醇(HDL-C)水平显著降低。盐酸西布曲明可减轻糖尿病肥胖大鼠的体重、内脏脂肪含量和系数,改善高胰岛素血症和胰岛素抵抗,降低血TG水平,同时升高HDL-C水平。对右比目鱼肌系数,血糖、总胆固醇和低密度脂蛋白胆固醇(LDL-C)水平,以及糖耐量无明显影响。结论:STZ联合高营养饲料可成功诱导糖尿病性肥胖的大鼠模型,盐酸西布曲明对大鼠糖尿病肥胖具有一定的治疗作用。     

小檗碱对高脂血症伴胰岛素抵抗大鼠糖脂代谢的影响

目的:观察小檗碱对高脂血症伴胰岛素抵抗(IR)大鼠糖脂代谢的影响,探讨其调脂和改善IR的机理.方法:通过喂养高脂饲料和小剂量静注链脲佐菌素(STZ)建立高脂血症伴IR大鼠模型,测定各不同处理组血糖、脂、胰岛素水平和脂代谢关键酶活性.结果:小檗碱组大鼠总胆固醇(TC)、甘油三酯(TG)、载脂蛋白B(ApoB)、低密度脂蛋白-胆固醇(LDL-C)、游离脂肪酸(FFA)均比模型组明显降低(P＜0.05或P＜0.01),而高密度脂蛋白-胆固醇(HDL-C)、载脂蛋白A(ApoAI)、胰岛素敏感指数(ISI)显著升高;血脂蛋白脂酶(LPL)活性显著升高(P＜0.05或P＜0.01).结论:小檗碱可能通过降低血FFA而改善IR,其调脂功效可能与升高LPL活性有关.     

丙丁酚对高脂血症小鼠表达C反应蛋白的影响

目的观察丙丁酚对高脂高胆固醇饲养的高脂血症小鼠体内C反应蛋白（CRP）活性及表达的影响，探讨丙丁酚的作用机制。方法以高脂高胆周醇饲料饲喂小鼠，制作高脂血症模型。HE染色观察小鼠肝脏病变情况；采用相关检测试剂盒测定小鼠血脂水平、血浆中CRP和谷胱甘肽S转移酶的活性；采用逆转录聚合酶链式反应（RT—PCR）检测小鼠肝脏CRP mRNA的表达。结果高脂高胆固醇饮食显著增加C57BL／6J和apoE^./.小鼠血脂水平（P〈0．05），而丙丁酚则可降低高脂血症小鼠血脂水平（P〈0．05）。高脂组小鼠肝脏结构比较紊乱，脂肪空泡明显。与高脂组比较，经丙丁酚处理后，小鼠肝脏的脂肪空泡明显减少，并且其血浆中CRP的水平也下降（P〈0．05）。结论丙丁酚可以减轻高脂高胆固醇饲料诱导的高脂血症小鼠的CRP的水平，对肝脏产生抗炎性的保护作用。     

造模持续时间对大鼠高营养性肥胖模型制备的影响

目的研究造模持续时间对大鼠高营养饮食诱导型肥胖(DIO)及其相关指标形成的影响。方法在3批实验中,断乳♂SD大鼠各290只,用相同配方的高营养饲料分别喂养7、9和10wk以建立DIO模型,然后分别给西布曲明8、4和4mg·kg-1共18、14和14d。实验指标包括体重、Lee′s指数、肝脏和腹腔脂肪湿重、血糖和血脂水平以及脂肪肝的形成。结果造模7wk的DIO大鼠体重、Lee′s指数、肝脏和脂肪湿重高于正常组;造模9wk的除以上指标有改变外,血TG水平也升高;造模10wk后,又同时出现血GLU水平的升高,且有明显的脂肪肝形成。结论造模的持续时间对DIO大鼠肥胖相关指标的形成有影响,应根据实际研究目的确定模型建立所需时间的长短。     

氢杨梅素改善高脂饮食诱导的肥胖小鼠肝脏脂肪沉积及机制（英文）

有文献报道, SIRT1-AMPK信号通路可能在DHM改善肝脏细胞甘油三酯蓄积、胰岛素抵抗等作用中发挥作用。为此,本课题拟进一步观察DHM对高脂饮食诱导的肥胖小鼠肝脏脂肪沉积的影响,并探讨其可能机制。C57BL/6J小鼠采用普通饲料和高脂饲料喂养,同时分别用或不用低剂量(125 mg/kg)或高剂量(250 mg/kg)的DHM处理16周。实验期间,每两周检测体重一次。16周后,眼眶静脉取血并处死动物,同时取肩胛下、附睾与腹股沟的脂肪并用电子秤进行称重,并记录脂肪重量。全自动生化分析仪检测:血清甘油三酯(triglyceride,TG)、血清总胆固醇(totalcholesterol,TC)、血清高密度脂蛋白(high-densitylipoprotein,HDL)、血清低密度脂蛋白(low-densitylipoprotein,LDL)。取肝脏甲醛固定、HE和油红O染色检测肝脏脂肪沉积情况;比色法检测肝脏MDA和SOD含量; Realtime PCR检测相关指标的基因表达:IL-6、IL-8、TNF-α、乙酰辅酶A羧化酶(acetyl-Co A carboxylase, ACC)、固...     

一种小鼠高脂血症新模型的建立

目的建立高脂血症实验动物模型新型方法。方法30只小鼠随机分为空白对照组、阳性对照组及模型组。空白对照组喂饲标准饲料,阳性对照组喂饲高脂饲料;模型组饲以标准饲料和牛奶,30d后检测血清和肝脏胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及肝脏指数(LI),光镜观察肝脏病理变化。结果与空白组相比,模型组LI及血液和血清中TC、TG、LDL-C明显升高,而HDL-C明显降低。光镜下模型组肝脏均出现弥漫性肝细胞脂肪变性和炎症病灶。结论小鼠喂饲30d标准饲料和牛奶,可建立理想的高脂血症模型。     

动脉粥样硬化高脂饲料对小鼠糖脂水平的作用研究

目的 研究动脉粥样硬化高脂饲料对小鼠体重、血糖血脂水平及动脉粥样硬化斑块形成的作用,并且明确禁食时间对血脂检测结果的影响.方法 对10周龄雄性ApoE基因敲除(ApoE-/-)小鼠分别给予高脂饲料及普通饲料,4个月后观察动脉粥样硬化斑块情况;对10周龄雄性C57BL/6J小鼠分别给予普通饲料4周、普通饲料2周+高脂饲料...     

Fenretinide ameliorates insulin resistance and fatty liver in obese mice

Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4. We investigated whether there is another possible mechanism by which fenretinide reduces insulin resistance and fatty liver in genetically obese (ob/ob) mice. Male obese mice fed a high-fat diet (45% of calories from fat) were divided into two groups (n=13 each). One (FEN) received fenretinide (20 mg/kg body weight, intraperitoneally) and the other (O) received vehicle three times weekly for 24 d. C57BL/6J mice fed a normal-fat diet (16% of calories from fat) were used as a control (C; n=13). No changes in fat weight and serum leptin level could be observed in FEN mice. Lower plasma RBP4 was observed in FEN mice compared with O mice. Fenretinide improved whole-body insulin sensitivity based on glucose and insulin tolerance tests and the homeostasis model assessment of insulin resistance. Fenretinide decreased the plasma lipid (triglyceride, cholesterol, and free-fatty acid) levels, hepatic TG level, and histological steatosis score. The mechanism by which fenretinide prevents fatty liver may be explained by an increased plasma adiponectin level, increased activation of hepatic AMP-activated protein kinase, and the expression of peroxisome proliferator-activated protein-α and peroxisomal acyl-CoA oxidase, which promote fat oxidation. FEN alleviated insulin resistance and fatty liver in obese mice and thus may act as an anti-lipidemic and anti-diabetic drug.     

高脂饲料诱发非酒精性脂肪肝实验研究

目的探讨正常饮食和高脂肪饮食对小鼠体重、血糖、葡萄糖耐受、血脂、脂肪肝的影响。方法雄性C57BL/6小鼠随机分为MD10%和MD45%脂肪含量饲料组,喂养3个月,检测动物体重、血糖、葡萄糖耐受、血脂,以及主要脏器重量及肝脏脂质含量。结果与正常组（MD10%脂肪含量）相比,高脂组（MD45%脂肪含量）动物体重显著增加,出现明显的糖耐量异常和血脂水平升高,同时伴有肝脏脂质含量增加。结论高脂饮食对非酒精性脂肪肝有较强的诱导作用。     

Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice

Lipid metabolism disorders contribute to hyperlipidemia and hepatic steatosis. It is ideal to develop drugs simultaneous improving both hyperlipidemia and hepatic steatosis. Nitazoxanide is an FDA-approved oral antiprotozoal drug with excellent pharmacokinetic and safety profile. We found that nitazoxanide and its metabolite tizoxanide induced mild mitochondrial uncoupling and subsequently activated AMPK in HepG2 cells. Gavage administration of nitazoxanide inhibited high-fat diet (HFD)-induced increases of liver weight, blood and liver lipids, and ameliorated HFD-induced renal lipid accumulation in hamsters. Nitazoxanide significantly improved HFD-induced histopathologic changes of hamster livers. In the hamsters with pre-existing hyperlipidemia and hepatic steatosis, nitazoxanide also showed therapeutic effect. Gavage administration of nitazoxanide improved HFD-induced hepatic steatosis in C57BL/6J mice and western diet (WD)-induced hepatic steatosis in Apoe^–/– mice. The present study suggests that repurposing nitazoxanide as a drug for hyperlipidemia and hepatic steatosis treatment is promising.     

Curcumin Attenuates Diet‐Induced Hepatic Steatosis by Activating AMP‐Activated Protein Kinase

Curcumin is a well‐known component of traditional turmeric (Curcuma longa), which has been reported to prevent obesity and diabetes. However, the effect of curcumin on hepatic lipid metabolism remains unclear. The aim of this study was to examine the effects of curcumin on hepatic steatosis in high‐fat/cholesterol diet (HFD)‐induced obese mice. Male C57BL/6J mice were fed a normal diet (ND), HFD or HFD with 0.15% curcumin (HFD+C) for 11 weeks. We found that curcumin significantly lowered the body‐weight and adipose tissue weight of mice in the HFD+C group compared with the findings for the HFD group (p < 0.05). The levels of total cholesterol, fasting glucose and insulin in serum were decreased, and HFD‐induced impairment of insulin sensitivity was improved by curcumin supplementation (p < 0.05). Curcumin protected against the development of hepatic steatosis by reducing hepatic fat accumulation. Moreover, curcumin activated AMP‐activated protein kinase (AMPK) and elevated the gene expression of peroxisome proliferator‐activated receptor alpha. By contrast, curcumin suppressed the HFD‐mediated increases in sterol regulatory element‐binding protein‐1, acetyl‐CoA carboxylase 1, fatty acid synthase and cluster of differentiation 36 expression. Taken together, these findings indicate that curcumin attenuates HFD‐induced hepatic steatosis by regulating hepatic lipid metabolism via AMPK activation, suggesting its use as a therapeutic for hepatic steatosis.     

Effect of oxymatrine on lipid metabolism regulated genes in liver of fat-induced insulin resistance in ApoE-/-mice北大核心CSCD

Aim To investigate the effect of oxymatrine on lipid metabolism regulated genes in liver in fat-induced insulin resistance in ApoE-/- mice. Methods Seventeen C57BL/6J male mice were selected in normal control group. Sixty-eight ApoE-/- mice with high fat diet for 16 weeks, were randomly divided into model group, oxymatrine low, middle and high dose groups. Then they were gavaged for 8 weeks. Body weight and general biochemical indicators were determined in mice. The mRNA and protein expression levels of LPL, FAT/CD36, CPT1, UCP2, SREBP-1 c, FAS and ACC were examined by real-time PCR and Western blot in the liver. Results Compared with model group, oxymatrine reduced body weight (BW) , fasting blood glucose (FBG), cholesterol (TC) , triglyceride (TG) , free fatty acids (FFA), fasting plasma insulin (FINS) and insulin resistance index(HOMA-IR) (P < 0. 05) , while improved glucose infusion rate (GIR) . Oxymatrine down-regulated the mRNA and protein expression of LPL, FAT/CD36, UCP2, SREBP-1c, FAS and ACC(P <0. 05) ,and up-regulated the mRNA and protein expression of CPT1 in varying degrees (P < 0. 05). Conclusion Oxymatrine can regulate the expression of lipid metabolism regulated genes in liver and improve insulin resistance in ApoE-/- mice induced by high fat diet.     

机械加载对高脂饮食诱导的肥胖和非酒精性脂肪肝的治疗作用

目的 探讨机械加载对高脂饮食诱导的肥胖和非酒精性脂肪肝的疗效。方法 选用6周龄的C57BL/6雌性小鼠30只,体质量约18 g,按随机数字表法分为正常对照组（NC组）、高脂饮食组（HF组）和高脂饮食机械加载治疗组（HF+L组）,每组10只,持续饮食诱导12周。高脂饮食6周后,HF+L组进行机械加载治疗6周。实验动物进行体成分分析,观测全身体脂含量的变化。收集肾周脂肪、子宫周脂肪、肠系膜脂肪、腹股沟脂肪和肝脏并称量湿质量。留取部分肝脏做组织形态学检测,油红O和HE染色分析观察肝脏的病理改变,部分肝脏用于Western blot检测内质网应激相关蛋白（eIF2α、p-eIF2α、ATF4）的表达。结果 与NC组相比,高脂饮食导致HF组体质量、体脂明显增加,机械加载治疗后,HF+L组体质量、体脂较HF组明显降低（P＜0.05）。肝脏组织学结果表明,高脂饮食导致一定程度的肝脏脂肪变性,通过治疗后,脂肪变性得到有效缓解（P＜0.05）。Western blot分析结果表明,高脂饮食导致小鼠肝脏eIF2α、p-eIF2α和ATF4蛋白表达升高,机械加载能够抑制肝脏p-eIF2α和ATF4蛋白的表达。结论 机械加载能够有效缓解高脂饮食导致的体质量、体脂增加及非酒精性脂肪肝,其治疗作用可能与肝脏内质网应激有关。     

双去甲氧基姜黄素对肥胖模型小鼠糖脂代谢的影响及机制

目的 研究双去甲氧基姜黄素(bisdemethoxycurcumin,BDMC)对高糖高脂饮食诱导的肥胖小鼠胰岛素抵抗、糖脂代谢紊乱的影响,并探讨其机制。方法 C57BL/6小鼠40只随机分为正常组(10只)和高糖高脂饮食组(30只),正常组小鼠给予常规饲料,其余小鼠饲喂高糖高脂饮食诱导肥胖,造模8周。造模成功后,高糖高脂饮食组小鼠随机分为模型组、BDMC低剂量组(20 mg·kg^-1)、BDMC高剂量组(40 mg·kg^-1),每组10只。分别按剂量灌胃给药,每日1次,每周5次,连续8周。给药结束后,检测小鼠体质量、肝脏及脂肪重量,观察肝脏病理改变及脂质堆积情况,监测小鼠血糖、血脂、血清胰岛素等生化指标,并考察BDMC对TRPV1、AMPK及下游胰岛素信号、糖脂代谢通路的影响。结果 与正常组相比,模型组小鼠体质量及脏器指数增加,肝脏出现明显的病理改变,脂质堆积严重,血清胰岛素、血糖、血脂参数(TC、TG、LDL-C)显著增高,HDL-C显著降低;肝损伤(ALT、AST)加重;肝脏组织中TRPV1、SREBP、FAS蛋白表达显著升高,p-IRS1、p-AMPK、GLUT4、p-ACC表达显著降低。与模型组相比,给予BDMC治疗后,肝脏脂质堆积减少,组织病理改变得到改善,血糖、血清胰岛素、TC、TG、LDL-C、ALT、AST显著降低(P<0.05),HDL-C显著升高,肝脏中p-IRS1、p-AMPK、GLUT4、p-ACC表达升高,TRPV1、SREBP、FAS表达显著降低(P<0.05)。结论 BDMC能改善胰岛素抵抗,调节糖脂代谢紊乱,治疗高糖高脂饮食诱导的肥胖,其作用可能与调节TRPV1和AMPK信号通路有关。     

二氢杨梅素经激活SIRT1-AMPK通路抑制高脂饮食诱导的肥胖小鼠肝脏脂质沉积

目的探究二氢杨梅素(dihydromyricetin,DHM)对高脂饮食诱导的肥胖小鼠肝脏脂质蓄积的作用及其机制。方法C57BL/6J小鼠60只,随机分为6组(n=10):①ND组:正常饲料;②ND+L-DHM组:正常饲料+低剂量DHM(125 mg·kg^-1·d^-1);③ND+H-DHM组:正常饲料+高剂量DHM(250 mg·kg^-1·d^-1);④HFD组:高脂饲料;⑤HFD+L-DHM组:高脂饲料+低剂量DHM;⑥HFD+H-DHM组:高脂饲料+高剂量DHM。记录小鼠体重;16周后,测空腹血脂;计算体脂重量;肝脏HE和油红O染色;荧光定量PCR和Western blot检测肝脏SIRT1、AMPK、ACC、FAS、SREBP-1和PPARα、CPT1的表达。结果与ND组相比,HFD组小鼠体重、体脂、血清TG、TC、HDL水平明显增加;肝脏内脂肪蓄积增加,肝脏SREBP-1c、FAS、ACC1表达增加,而PPARα、CPT1、SIRT1和AMPK表达下降。经DHM处理后,HFD小鼠上述指标发生逆转;但ND小鼠上述指标无明显改变。结论DHM可能通过激活SIRT1-AMPK通路抑制脂质合成,促进脂质分解,改善高脂饮食诱导的肥胖小鼠肝脏脂质沉积。